Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Department of Cardiology, Université Paris-Descartes, and INSERM U-970, Paris, France.
JAMA. 2012 Sep 12;308(10):998-1006. doi: 10.1001/2012.jama.11348.
The contemporary decline in mortality reported in patients with ST-segment elevation myocardial infarction (STEMI) has been attributed mainly to improved use of reperfusion therapy.
To determine potential factors-beyond reperfusion therapy-associated with improved survival in patients with STEMI over a 15-year period.
DESIGN, SETTING, AND PATIENTS: Four 1-month French nationwide registries, conducted 5 years apart (between 1995, 2000, 2005, 2010), including a total of 6707 STEMI patients admitted to intensive care or coronary care units.
Changes over time in crude 30-day mortality, and mortality standardized to the 2010 population characteristics.
Mean (SD) age decreased from 66.2 (14.0) to 63.3 (14.5) years, with a concomitant decline in history of cardiovascular events and comorbidities. The proportion of younger patients increased, particularly in women younger than 60 years (from 11.8% to 25.5%), in whom prevalence of current smoking (37.3% to 73.1%) and obesity (17.6% to 27.1%) increased. Time from symptom onset to hospital admission decreased, with a shorter time from onset to first call, and broader use of mobile intensive care units. Reperfusion therapy increased from 49.4% to 74.7%, driven by primary percutaneous coronary intervention (11.9% to 60.8%). Early use of recommended medications increased, particularly low-molecular-weight heparins and statins. Crude 30-day mortality decreased from 13.7% (95% CI, 12.0-15.4) to 4.4% (95% CI, 3.5-5.4), whereas standardized mortality decreased from 11.3% (95% CI, 9.5-13.2) to 4.4% (95% CI, 3.5-5.4). Multivariable analysis showed a consistent reduction in mortality from 1995 to 2010 after controlling for clinical characteristics in addition to the initial population risk score and use of reperfusion therapy, with odds mortality ratios of 0.39 (95%, 0.29-0.53, P <.001) in 2010 compared with 1995.
In France, the overall rate of cardiovascular mortality among patients with STEMI decreased from 1995 to 2010, accompanied by an increase in the proportion of women younger than 60 years with STEMI, changes in other population characteristics, and greater use of reperfusion therapy and recommended medications.
ST 段抬高型心肌梗死(STEMI)患者报告的当代死亡率下降主要归因于再灌注治疗的改善。
确定与 STEMI 患者 15 年期间生存率提高相关的除再灌注治疗以外的潜在因素。
设计、地点和患者:4 项为期 1 个月的法国全国注册研究,每 5 年进行一次(1995 年、2000 年、2005 年和 2010 年),共纳入 6707 例 STEMI 患者入住重症监护或冠心病监护病房。
30 天粗死亡率的时间变化,以及按 2010 年人口特征标准化的死亡率。
平均(标准差)年龄从 66.2(14.0)岁降至 63.3(14.5)岁,心血管事件和合并症的历史也随之下降。年轻患者的比例增加,尤其是 60 岁以下的女性(从 11.8%增加到 25.5%),在此期间,目前吸烟(从 37.3%增加到 73.1%)和肥胖(从 17.6%增加到 27.1%)的患病率增加。从症状发作到入院的时间缩短,从发作到首次呼叫的时间更短,移动重症监护室的使用范围更广。再灌注治疗的使用率从 49.4%增加到 74.7%,主要得益于经皮冠状动脉介入治疗(从 11.9%增加到 60.8%)。推荐药物的早期使用增加,尤其是低分子肝素和他汀类药物。30 天粗死亡率从 13.7%(95%CI,12.0-15.4)降至 4.4%(95%CI,3.5-5.4),而标准化死亡率从 11.3%(95%CI,9.5-13.2)降至 4.4%(95%CI,3.5-5.4)。多变量分析显示,除了初始人群风险评分和再灌注治疗的使用外,1995 年至 2010 年期间,临床特征控制后死亡率持续下降,2010 年与 1995 年相比,死亡比值比为 0.39(95%CI,0.29-0.53,P<0.001)。
在法国,STEMI 患者的总体心血管死亡率从 1995 年至 2010 年下降,同时 60 岁以下 STEMI 女性的比例增加,其他人口特征发生变化,再灌注治疗和推荐药物的使用也有所增加。